Logo CMEO

Bench to Bedside OnDemand:

The Growing (Anti)body of Evidence for the Treatment of Mild-to-Moderate COVID-19

Credit offered for:

  • Physicians

    American Board of Internal Medicine Maintenance of Certification (ABIM MOC)

  • Nurses
  • Pharmacists
  • Certificate of completion

Link to CME Outfitters activity page

Please click here to visit the CME Outfitters activity page

Statement of Need

The novel SARS-CoV-2 virus caused the rapid global spread of COVID-19, and while coronavirus is often mild and self-limiting, approximately 10% of mild SARS-CoV-2 infections progress to severe symptoms, including respiratory distress syndrome, and up to 20% of symptomatic patients develop critical disease with clinical complications including pneumonia and hyper-inflammation. Several repurposed drugs have been used to treat patients hospitalized with serious COVID-19 disease, with monoclonal antibodies (mAbs) being one of the first therapies offered by the FDA. But despite promising results, the demand for treatment for mild-to-moderate COVID-19 has not met expectations, as many health care providers may not be familiar with or aware that preventative treatments are available for mild-to-moderate COVID-19.

This CME Outfitters Live and OnDemand on early intervention treatments following diagnosis of COVID-19 as a way to reduce progression to severe disease will include the latest data on the efficacy and safety of mAb therapies and strategies for addressing knowledge and practice barriers to improve patient access to these therapies.

Learning Objectives

At the end of this CE activity, participants should be able to:

  • Integrate screening assessments for the early and accurate diagnosis of mild-to-moderate COVID-19 to guide treatment decision-making in high-risk patient groups.
  • Apply the latest data on the efficacy and safety of monoclonal antibody therapies to treatment decisions for patients with mild-to-moderate COVID-19.
  • Implement strategies to address knowledge and practice barriers to patient access to infusion service for monoclonal antibody therapy.

The following learning objectives pertain only to those requesting CNE or CPE credit:

  • Summarize screening assessments used for the early and accurate diagnosis of mild-to-moderate COVID-19 to guide treatment decision-making in high-risk patient groups.
  • Discuss the latest data on the efficacy and safety of monoclonal antibody therapies to treatment decisions for patients with mild-to-moderate COVID-19.
  • Describe strategies to address knowledge and practice barriers to patient access to infusion service for monoclonal antibody therapy.

Financial Support

This activity is supported by an educational grant from Lilly. For further information concerning Lilly grant funding visit www.lillygrantoffice.com

Target Audience

Physicians, PAs, nurse practitioners, nurses, infusion center nurses, and pharmacists.

Additional Credit Information

UEMS-EACCME (Europe):

Through a mutual recognition agreement between the AMA and the UEMS-EACCME, European physicians completing an e-learning activity from a US-based ACCME-accredited CME provider can use AMA PRA Category 1 Credit™ toward their credit requirements. CME Outfitters is based in Bethesda, Maryland, USA. Please retain your certificate as proof of completion.

Additionally, the following Countries and Regions have reciprocity with the ACCME:

  • Austrian Academy of Physicians (Austria)
  • Bavarian Chamber of Physicians (Germany)
  • Bulgarian Union of Scientific Medical Societies (Bulgaria)
  • Federation of Royal Colleges of Physicians (UK)
  • French National Medical Council (France)
  • Italian Federation of Scientific Medical Societies (Italy)
  • National CME Commission of the Italian Ministry of Health (Italy)
  • Spanish Accreditation Council for CME (Spain)
  • Turkish Medical Association (Turkey)

Royal College MOC (Canada):

Through an agreement between the Accreditation Council for Continuing Medical Education and the Royal College of Physicians and Surgeons of Canada, medical practitioners participating in the Royal College MOC Program may record completion of accredited activities registered under the ACCME’s “CME in Support of MOC” program in Section 3 of the Royal College’s MOC Program.

Qatar Department of Healthcare Professions:

Through a mutual recognition agreement between the AMA and the DHP, physicians licensed in Qatar completing an activity from a US-based ACCME-accredited CME provider can use AMA PRA Category 1 Credit™ toward their credit requirements.

Department of Health-Abu Dhabi (UAE):

The Department of Health-Abu Dhabi recognizes CME programs which are accredited by the Accreditation Council for Continuing Medical Education (ACCME).

Non-US-based Pharmacists:

Official pharmacist credit is recorded in the CPE Monitor and requires all pharmacists to have an e-Profile with the National Association of Boards of Pharmacy (NABP). For more information on what is needed to create an NABP e-Profile, please visit: https://nabp.pharmacy/help/?answer=43715#611

Link to CME Outfitters activity page

Please click here to visit the CME Outfitters activity page

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Chen reports that he is on the advisory board for Eli Lilly and Company.

Dr. Huhn reports that he receives grants and research support from Eli Lilly and Company; Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; and ViiV Healthcare. He is on the advisory board for Gilead Sciences, Inc.; Janssen Pharmaceuticals, Inc.; and ViiV Healthcare.

Dr. Savoy has no disclosures to report.

Tony Graham, MD (peer reviewer) has no disclosures to report.

Maria Glukhovsky, PharmD (planning committee) has no disclosures to report.

Jan Perez (planning committee) has no disclosures to report.

Sharon Tordoff (planning committee) has no disclosures to report.

Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.